These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 12888583)

  • 41. [Antimicrobial effects of erythromycin microspheres against Mycoplasma Pneumoniae in rats].
    Li T; Wen J; Jiang WL; Gong M; Yang ZQ; Xiao H
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct; 28(10):1875-7. PubMed ID: 18971193
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Factors influencing the intracellular activity of fluoroquinolones: a study using levofloxacin in a Staphylococcus aureus THP-1 monocyte model.
    Nguyen HA; Grellet J; Paillard D; Dubois V; Quentin C; Saux MC
    J Antimicrob Chemother; 2006 May; 57(5):883-90. PubMed ID: 16533826
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Is activity against "atypical" pathogens necessary in the treatment protocols for community-acquired pneumonia? Issues with combination therapy.
    Bartlett JG
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S232-6. PubMed ID: 18986295
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro activity of parenteral Beta-lactams, levofloxacin and tobramycin alone or in combination against extended-spectrum Beta-lactamase producing Klebsiella pneumoniae.
    Burgess DS; Hall RG
    Int J Antimicrob Agents; 2004 Jul; 24(1):48-52. PubMed ID: 15225861
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of ofloxacin activity against recent clinical isolates.
    Nani E; Anzivino D; Lavitola A; Lembo M; Covelli B
    J Chemother; 1989 Jul; 1(4 Suppl):145-6. PubMed ID: 16312345
    [No Abstract]   [Full Text] [Related]  

  • 46. Ceftriaxone acts synergistically with levofloxacin in experimental meningitis and reduces levofloxacin-induced resistance in penicillin-resistant pneumococci.
    Flatz L; Cottagnoud M; Kühn F; Entenza J; Stucki A; Cottagnoud P
    J Antimicrob Chemother; 2004 Feb; 53(2):305-10. PubMed ID: 14729741
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by Klebsiella pneumoniae deficient in porins, expressing active efflux and producing QnrA1.
    Rodríguez-Martínez JM; Pichardo C; García I; Pachón-Ibañez ME; Docobo-Pérez F; Pascual A; Pachón J; Martínez-Martínez L
    Clin Microbiol Infect; 2008 Jul; 14(7):691-7. PubMed ID: 18558942
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease.
    Conte JE; Golden JA; McIver M; Little E; Zurlinden E
    Int J Antimicrob Agents; 2007 Nov; 30(5):422-7. PubMed ID: 17716873
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I; Cars O
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Precursor-directed biosynthesis of micacocidin derivatives with activity against Mycoplasma pneumoniae.
    Kreutzer MF; Kage H; Herrmann J; Pauly J; Hermenau R; Müller R; Hoffmeister D; Nett M
    Org Biomol Chem; 2014 Jan; 12(1):113-8. PubMed ID: 24202877
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.
    Touyama M; Higa F; Nakasone C; Shinzato T; Akamine M; Haranaga S; Tateyama M; Nakasone I; Yamane N; Fujita J
    J Antimicrob Chemother; 2006 Dec; 58(6):1279-82. PubMed ID: 17056610
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae.
    Hammerschlag MR; Roblin PM
    J Antimicrob Chemother; 2004 Jul; 54(1):281-2. PubMed ID: 15190026
    [No Abstract]   [Full Text] [Related]  

  • 53. [Bacterial resistances].
    García Sánchez MJ; González Rojas ME; García Cuadros M; Seguido Aliaga P
    Aten Primaria; 1999 Nov; 24(8):499-500. PubMed ID: 10630037
    [No Abstract]   [Full Text] [Related]  

  • 54. [Should presumptive meningoencephalitis treatment in adults be active against Mycoplasma pneumoniae?].
    Trouillier S; Dionet E; Bocquier B; Constantin JM; Guelon D; Bonnet R; Romaszko JP; Laurichesse H; Beytout J; Lesens O
    Med Mal Infect; 2007 Nov; 37(11):738-45. PubMed ID: 17434700
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [In vitro activity of levofloxacin against Escherichia coli strains in acute pyelonephritis, in France in 2005].
    Soussy CJ; Lascols C; Dib-Smahi C;
    Med Mal Infect; 2007 Nov; 37(11):773-5. PubMed ID: 17936533
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Invasive Haemophilus influenzae isolates with decreased levofloxacin susceptibility in Hong Kong.
    Ho PL; Mak GC; Tse CW; Chow KH; Cheung CH
    J Antimicrob Chemother; 2006 Feb; 57(2):366. PubMed ID: 16387750
    [No Abstract]   [Full Text] [Related]  

  • 57. Longitudinally tracking fluoroquinolone resistance and its determinants in penicillin-susceptible and -nonsusceptible Streptococcus pneumoniae isolates in Hong Kong, 2000 to 2005.
    Ip M; Chau SS; Chi F; Cheuk ES; Ma H; Lai RW; Chan PK
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2192-4. PubMed ID: 17371818
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro development of resistance to six and four fluoroquinolones in Mycoplasma pneumoniae and Mycoplasma hominis, respectively.
    Gruson D; Pereyre S; Renaudin H; Charron A; Bébéar C; Bébéar CM
    Antimicrob Agents Chemother; 2005 Mar; 49(3):1190-3. PubMed ID: 15728924
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP).
    Noreddin AM; Marras TK; Sanders K; Chan CK; Hoban DJ; Zhanel GG
    Int J Antimicrob Agents; 2004 Nov; 24(5):479-84. PubMed ID: 15519481
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Congenital Mycoplasma pneumoniae pneumonia in a neonate.
    Srinivasjois RM; Kohan R; Keil AD; Smith NM
    Pediatr Infect Dis J; 2008 May; 27(5):474-5. PubMed ID: 18360299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.